Peppermint oil
CAS 8006-90-4
Peppermint oil (CAS 8006-90-4) is a pharmaceutical compound with 0 bioactivity targets and 285 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Peppermint oil is linked to DTXSID6021113 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| PEPPERMINT OIL | 33094 | SU | MTHSPL |
| Peppermint Oil | 33094 | SU | MTHSPL |
| Peppermint oil | 33094 | SU | MTHSPL |
| peppermint oil | 33094 | SU | MTHSPL |
| peppermint oil | 33094 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Peppermint oil used for in pharmaceutical contexts?
Peppermint oil (CAS 8006-90-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Peppermint oil?
Peppermint oil has 285 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Atrial fibrillation, Brain natriuretic peptide increased, Bronchospasm, Cardiac disorder, Chest discomfort. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Peppermint oil also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Mentha Piperita Oil with EU status "restricted".
What clinical phase is Peppermint oil in?
No phase 1-4 clinical development badge is rendered for Peppermint oil because the matched compound identifier rows do not contain a max-phase value.